for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alkem Laboratories Ltd

ALKE.NS

Latest Trade

2,085.60INR

Change

-1.80(-0.09%)

Volume

27,838

Today's Range

2,083.25

 - 

2,100.00

52 Week Range

1,660.00

 - 

2,150.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
2,087.40
Open
2,096.00
Volume
27,838
3M AVG Volume
1.05
Today's High
2,100.00
Today's Low
2,083.25
52 Week High
2,150.00
52 Week Low
1,660.00
Shares Out (MIL)
119.57
Market Cap (MIL)
248,617.50
Forward P/E
24.10
Dividend (Yield %)
0.77

Latest Developments

More

India's Alkem Laboratories Sept Quarter Consol Profit Rises

Alkem Laboratories Says Closure Of US FDA Inspection At Manufacturing Facilities Located At Daman And Baddi

India's Alkem Labs Says No Form 483 Issued After FDA Inspection at Taloja

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alkem Laboratories Ltd

Alkem Laboratories Limited is a pharmaceutical company. The Company is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates through two segments: pharmaceutical and investing. The Company produces generics, generic drugs, active pharmaceutical ingredients (APIs) and neutraceuticals, which it markets in India and approximately 50 countries internationally, primarily the United States. The Company offers various products, such as CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, among others. The Company has approximately 16 manufacturing facilities, of which 14 manufacturing facilities are at geographically diversified locations in India and two in the United States.

Industry

Biotechnology & Drugs

Contact Info

Almac House, Senapati Bapat Marg

+91.22.39829999

https://www.alkemlabs.com/

Executive Leadership

Basudeo Narain Singh

Executive Chairman of the Board

Rajesh Dubey

Chief Financial Officer

Amit Ghare

President - International Business

Girish Jain

President – Research and Development

Venkatesh S.

President and Chief Executive Officer of Ascend Laboratories LLC

Key Stats

1.71 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

58.5K

2018

64.3K

2019

73.6K

2020(E)

82.6K
EPS (INR)

2017

74.610

2018

52.770

2019

63.610

2020(E)

86.291
Price To Earnings (TTM)
26.84
Price To Sales (TTM)
3.15
Price To Book (MRQ)
4.23
Price To Cash Flow (TTM)
21.42
Total Debt To Equity (MRQ)
24.07
LT Debt To Equity (MRQ)
5.68
Return on Investment (TTM)
15.63
Return on Equity (TTM)
11.09

Latest News

Latest News

BRIEF-FDA Approves A New Generic Valsartan

* U.S. FDA - APPROVAL OF NEW GENERIC OF DIOVAN WAS GRANTED TO ALKEM LABORATORIES LIMITED

India's Alkem Labs gets USFDA report about Amaliya unit

India's Alkem Labs Ltd said on Wednesday the United States Food and Drug Administration (USFDA) has issued a report about its Amaliya facility, citing 13 observations following an inspection.

BRIEF-Alkem Laboratories Gets Form 483 With 13 Observations After U.S. FDA Inspection At Co's Amaliya Facility​

* GOT A FORM 483 WITH 13 OBSERVATIONS AFTER US FDA INSPECTION AT CO'S MANUFACTURING FACILITY AT AMALIYA, DAMAN

BRIEF-India's Alkem Laboratories Dec Qtr Consol Profit Falls

* DEC QUARTER CONSOL PROFIT 1.72 BILLION RUPEES VERSUS 2.33 BILLION RUPEES YEAR AGO

BRIEF-Alkem Laboratories Announces Closure of U.S.FDA Inspection at Baddi Manufacturing Facility

* SAYS U.S. FDA ISSUES EIR FOR CO'S MANUFACTURING FACILITY AT BADDI

BRIEF-India's Alkem Laboratories Gets Shareholders' Nod For Appointment Of Sandeep Singh As MD

* GETS SHAREHOLDERS' NOD FOR APPOINTMENT OF SANDEEP SINGH AS MD

BRIEF-Alkem Labs Seeks Shareholders' Nod To Appoint Sandeep Singh As MD

* SEEKS SHAREHOLDERS' NOD TO RE-APPOINT DHANANJAY KUMAR SINGH AS JOINT MD Source text - http://bit.ly/2jn04KA Further company coverage:

BRIEF-India's Alkem Labs Sept-qtr consol profit rises

* Sept quarter consol profit 3.27 billion rupees versus 2.88 billion rupees year ago

BRIEF-India's Alkem Laboratories CEO Prabhat Agrawal resigns

Alkem Laboratories Ltd * Says Prabhat Agrawal resigns as CEO Source text - http://bit.ly/2xDyT3e Further company coverage:

BRIEF-Alkem Labs re-designates ‍Sandeep Singh as MD

* sandeep Singh appointed and re-designated as managing director

BRIEF-Alkem laboratories gets inspection report from US FDA with two 483 observations

* Says has received inspection report which contains two 483 observations

BRIEF-India's Alkem Laboratories June-qtr consol net profit falls

* June quarter consol net profit 637.8 million rupees versus profit of 2.43 billion rupees year ago

BRIEF-India's Alkem Laboratories March-qtr consol profit rises

* March quarter consol profit 1.37 billion rupees versus profit 865.4 million rupees year ago

BRIEF-Alkem Labs says US FDA issues EIR for Baddi manufacturing facility

* Says US FDA has issued an establishment inspection report for its Baddi manufacturing facility

BRIEF-Alkem Labs says FDA finds 3 adverse observations at co's Baddi facility

* Says us fda inspection at alkem's baddi facility Source text: http://bit.ly/2mP8JZl Further company coverage:

BRIEF-Alkem Laboratories Dec-qtr profit rises

* Dec quarter net profit 2.14 billion rupees versus profit2.13 billion rupees year ago

BRIEF-Alkem Labs to exclusively market Tiger Balm products in India

* Says Alkem enters into a strategic alliance with Haw Par to exclusively market, sell and distribute Tiger Balm products in India

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up